

# Impact of Patient Recall and Reporting Intervals on Real-World Attack Reductions After Berotralstat Initiation in Hereditary Angioedema Patients without C1-Inhibitor Deficiency

**Lorena Lopez-Gonzalez<sup>1</sup>, Sean D. MacKnight<sup>2</sup>, François Laliberté<sup>2</sup>, Robert C. Schell<sup>3</sup>, Sandra Nestler-Parr<sup>1</sup>, Meri LiVecchi<sup>1</sup>, Patrick Gillard<sup>1</sup>**

*<sup>1</sup>BioCryst Pharmaceuticals, Durham, NC, USA; <sup>2</sup>Groupe d'Analyse, Ltée, Montreal, QC, Canada; <sup>3</sup>Analysis Group, Inc., Menlo Park, CA, USA*

**Figure S1. Eligibility Criteria and Patient Disposition**

